Novo Nordisk Pharmatech

News

Novo CEO’s 1st Test Is Winning Back US Weight-Loss Market

The Wall Street Journal on MSN · 4h

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?

Danish leader will face a challenging landscape among competitors

Reuters on MSN · 21h

Novo Nordisk slides further on US competition, new CEO concerns

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs in the United States, a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value.

Bloomberg on MSN · 19h

Novo CEO’s First Test Is Winning Back the US Weight-Loss Market

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years after Wegovy’s US launch, the Danish drugmaker’s growth is slowing. About one million patients in the US are taking cheaper copycat options.

Novo Nordisk shares plummet

Opinion

The Motley Fool on MSN · 16h

Why Novo Nordisk Stock Plummeted Today

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, patient investors could find opportunity as the stock falls.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Plummet as Competition Weighs on Sales

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Fast Company on MSN · 1d

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than 57%. And since the beginning of 2025, the company’s share price has declined more than 35%. As of the time of this writing, NVO shares are down just over 20% this morning to $55.17 per share.

1don MSN

Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Novo Nordisk: Catch That Falling Knife

Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.

1don MSN

Ozempic maker Novo Nordisk has its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Hosted on MSN2mon

Novo Nordisk's CEO is out after the Ozempic maker's stock dropped ... - MSN

The move comes after Novo Nordisk’s share price fell 50% over the last 12 months, and amid growing pressure from the powerful Novo Nordisk Foundation, which controls the company’s voting ...

The Motley Fool2mon

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in ...

Novo Nordisk has an estimated 62% market share of the GLP-1 agonist market, with archrival Eli Lilly accounting for another 35%. Investors are looking ahead to next-generation drugs that could ...

The New York Times2mon

Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs

Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased competition for its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results